Literature DB >> 25389728

Reversible mental status change and renal dysfunction associated with the use of high-dose oral valaciclovir therapy for acute retinal necrosis.

Richard M H Lee1, Martin Llewellyn, Angela Houston, Edward H Hughes.   

Abstract

PURPOSE: The purpose of this study was to report the case of a patient with acute retinal necrosis who developed neurotoxicity while being treated with oral valaciclovir antiviral therapy.
METHODS: Testing used was clinical examination including fundus photographs, renal biochemistry, cerebrospinal fluid analysis, and renal ultrasound.
RESULTS: A 63-year-old, healthy, white woman was being treated with oral valaciclovir for acute retinal necrosis. Several days later, she developed visual hallucinations and confusion. Renal biochemistry was abnormal, and renal ultrasound was normal. Cerebrospinal fluid cellularity was normal, but cerebrospinal fluid 9-carboxymethoxymethylguanine, an aciclovir metabolite, level was elevated. Treatment was changed to intravenous aciclovir titrated based on serum aciclovir levels with intravenous fluid supplementation to good effect.
CONCLUSION: Regular monitoring of renal function and ample fluid intake are important when high doses of aciclovir/valaciclovir are used, even in patients with no previous history of renal failure. Monitoring of serum aciclovir level is useful in those with renal impairment to titrate doses, and high-dose oral valaciclovir should be used with caution.

Entities:  

Year:  2012        PMID: 25389728     DOI: 10.1097/ICB.0b013e3182252859

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  2 in total

1.  Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis.

Authors:  Bhanu Prasad; Mark McIsaac; Julie Toppings
Journal:  BMJ Case Rep       Date:  2017-07-31

Review 2.  Current aspects on the management of viral uveitis in immunocompetent individuals.

Authors:  Uwe Pleyer; Soon-Phaik Chee
Journal:  Clin Ophthalmol       Date:  2015-06-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.